This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay D treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
VP Research & Development
Is leading BrainsWay’s Research and Product Development departments.
Prior to this, Moria served as head of Biomedical Engineering Department and held the position of Project Management Officer.
Moria brings with her considerable experience and expertise in regulatory affairs, and comprehensive knowledge of brain stimulation technologies in general and of TMS in particular.
Moria holds a BSc. in Biomedical Engineering from the Jerusalem College of technology (JCT) with specializations in electro-optics.
Moria is driven by a passion to advance the development of BrainsWay’s future and existing product line as part of the ever-expanding neurostimulation market.